title: Definition of a critical T cell threshold for prevention of GVHD after HLA non-identical PBPC transplantation in children.
abstract: The aim of this study was to reduce the rate of graft failure after HLA non-identical stem cell transplantation by using G-CSF mobilized CD34+ peripheral blood progenitor cells (PBPC), either in combination with bone marrow or as single grafts. To prevent GVHD, PBPC were highly purified, resulting in a 5 to 6 log T cell depletion. In additon to T cell depletion no further GVHD prophylaxis was used. We transplanted 23 pediatric patients with life-threatening malignant or non-malignant hematological disorders, who had no available matched donor. Engraftment was obtained in 18 of 21 evaluable patients. Five patients developed acute GVHD of grade II and III, which became chronic in four cases and was fatal in four. The use of highly purified PBPC allowed the exact quantification of residual T cells in the grafts and a strict correlation between the residual T cell load and the development of GVHD was observed: patients with GVHD had received numbers of T cells between 8 and 20 x 104/kg, whereas patients without GVHD were grafted with T cell numbers ranging from 0.7 to 6.0 x 104/kg. We therefore clearly demonstrate that a residual T cell content of <5 x 104/kg is safe for prevention of GVHD after HLA non-identical PBPC transplantation in children.
authors.affiliation: Department of Pediatrics, Children's Hospital, University of Ulm, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Müller
authors.forename: A
authors.initials: A
authors.lastname: Schulz
authors.forename: U
authors.initials: U
authors.lastname: Reiss
authors.forename: K
authors.initials: K
authors.lastname: Schwarz
authors.forename: T
authors.initials: T
authors.lastname: Schreiner
authors.forename: M
authors.initials: M
authors.lastname: Wiesneth
authors.forename: K M
authors.initials: KM
authors.lastname: Debatin
authors.forename: W
authors.initials: W
authors.lastname: Friedrich
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006650:Histocompatibility Testing; D006801:Humans; D007223:Infant; D008297:Male; D013601:T-Lymphocytes / Q000276:immunology*